Tanja Limberger awarded Carl von Rokitansky-Prize

Tanja Limberger was awarded the Carl von Rokitansky-Prize at the autumn meeting of the Austrian Society for Clinical Pathology and Molecular Pathology. As lead author of a research team led by Lukas Kenner from MedUni Vienna's Clinical Institute of Pathology as part of a joint project with CBmed (Centre for Biomarker Research in Medicine), a COMET K1 centre funded by the Austrian Research Promotion Agency (FFG), Tanja Limberger studied the causes of metastasis in prostate cancer. The study was published in the prestigious journal Molecular Cancer. The -KMT2C Methyltransferase Domain regulated INK4A expression suppresses Prostate Cancer metastasis- study was published in the highly respected Molecular Cancer journal on 30 March 2022. For her outstanding achievement in the field of pathology, lead author Tanja Limberger was awarded the Carl von Rokitanksy Prize, sponsored by Roche, at the autumn meeting of the Austrian Society for Clinical Pathology and Molecular Pathology, which is bestowed in memory of the Austrian pathologist Carl von Rokitansky (1804-1878). The study investigated the role of the KMT2C protein in prostate cancer. KMT2C is a genetic component that plays a key role in regulating important cell processes.